Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Ep...( Adjusted EPS exclu...),Health

Adjusted EPS excluding selected items:

EURO 1.43, up 1.4%

$2.14, up 15.7%(1)

PARIS, April 30 /PRNewswire-FirstCall/ -- In order to give a representation of our underlying economic performance, we present and explain an adjusted income statement. We also report adjusted net income and adjusted EPS (excluding selected items) in U.S. dollars(1) in order to facilitate comparisons with the majority of major pharmaceutical groups. Consolidated net income for the first quarter of 2008 was EURO 1,325 million, compared with EURO 1,537 million for the first quarter of 2007.

Operating Results

* Net sales: EURO 6,937 million, up 0.8% on a comparable basis

(-3.3% reported)

* Net sales growth of 7.2%(2) for the Pharmaceuticals business, excluding

the impact of generics of Ambien(R) IR in the United States and

Eloxatin(R) in Europe(3), in line with previous quarters

* Strong growth(2) for Plavix(R) (18.9%), Lovenox(R) (21.5%), Lantus(R)

(30.8%), and Taxotere(R) (13.3%)

* Ongoing cost control and adaptation measures

* Adjusted net income excluding selected items: EURO 1,883 million, or

EURO 1.43 per share

Research & Development

* Positive results from GEMS, the third Phase III trial evaluating

eplivanserin in sleep quality Filing for approval scheduled for the

second half of 2008

* Agreement with Dyax on a human monoclonal antibody and on Phage Display

technology

Confirmation of 2008 Guidance

The first-quarter results support 2008 full-year guidance at constant EURO/dollar parity (1.371), as announced on February 12 (refer to 2008 Guidance section).

2008 first-quarter net sales

Unless otherwise indicated, all sales growth figures in this press release are stated on a comparable basis.

Sanofi-aventis generated first-qua
'/>"/>